Way 100135

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526561

CAS#: 133025-23-7

Description: Way 100135 is a serotonergic drug of the phenylpiperazine family which is used in scientific research. It acts as potent 5-HT1A receptor antagonist, and was originally believed to be highly selective, but further studies have demonstrated that it also acts as a partial agonist of the 5-HT1D receptor (pKi = 7.58; virtually the same affinity for 5-HT1A), and to a much lesser extent, of the 5-HT1B receptor (pKi = 5.82). These findings may have prompted the development of the related compound WAY-100,635, another purportedly selective and even more potent 5-HT1A antagonist, which was synthesized shortly thereafter.

Price and Availability


USD 230


Way 100135, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received. Delivery time: overnight (USA/Canada); 3-5 days (worldwide).

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 526561
Name: Way 100135
CAS#: 133025-23-7
Chemical Formula: C24H33N3O2
Exact Mass: 395.2573
Molecular Weight: 395.547
Elemental Analysis: C, 72.88; H, 8.41; N, 10.62; O, 8.09

Synonym: Way100135; Way-100135; Way 100135

IUPAC/Chemical Name: N-(tert-butyl)-3-(4-(2-methoxyphenyl)piperazin-1-yl)-2-phenylpropanamide


InChi Code: InChI=1S/C24H33N3O2/c1-24(2,3)25-23(28)20(19-10-6-5-7-11-19)18-26-14-16-27(17-15-26)21-12-8-9-13-22(21)29-4/h5-13,20H,14-18H2,1-4H3,(H,25,28)


Technical Data

White to off-white solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Kazmierska P, Konopacki J. Development of theta rhythm in hippocampal formation slices perfused with 5-HT1A antagonist, (S)WAY 100135. Brain Res. 2015 Nov 2;1625:142-50. doi: 10.1016/j.brainres.2015.08.041. Epub 2015 Sep 7. PubMed PMID: 26358147.

2: Wedzony K, Maćkowiak M, Zajaczkowski W, Fijał K, Chocyk A, Czyrak A. WAY 100135, an antagonist of 5-HT1A serotonin receptors, attenuates psychotomimetic effects of MK-801. Neuropsychopharmacology. 2000 Nov;23(5):547-59. PubMed PMID: 11027920.

3: Lopez-Mendoza D, Aguilar-Bravo H, Swanson HH. Combined effects of Gepirone and (+)WAY 100135 on territorial aggression in mice. Pharmacol Biochem Behav. 1998 Sep;61(1):1-8. PubMed PMID: 9715801.

4: Nakai K, Fujii T, Fujimoto K, Suzuki T, Kawashima K. Effect of WAY-100135 on the hippocampal acetylcholine release potentiated by 8-OH-DPAT, a serotonin1A receptor agonist, in normal and p-chlorophenylalanine-treated rats as measured by in vivo microdialysis. Neurosci Res. 1998 May;31(1):23-9. PubMed PMID: 9704975.

5: Boksa J, Klodzińska A, Charakchieva-Minol S, Chojnacka-Wójcik E, Mokrosz JL. Structure-activity relationship studies of CNS agents. Part 24: New analogs of N-tert.-butyl-3-[4-(2-methoxyphenyl)-1-piperazinyl]-2-phenylpropanamide (WAY-100135). Pharmazie. 1996 Feb;51(2):72-6. PubMed PMID: 8720802.

6: Rodgers RJ, Cole JC. Anxiolytic-like effect of (S)-WAY 100135, a 5-HT1A receptor antagonist, in the murine elevated plus-maze test. Eur J Pharmacol. 1994 Aug 22;261(3):321-5. PubMed PMID: 7813555.

7: Hartley JE, Fletcher A. The effects of WAY-100135 and 8-hydroxy-2-(di-n-propylamino)tetralin on feeding in the rat. Eur J Pharmacol. 1994 Feb 11;252(3):329-32. PubMed PMID: 8162954.

8: Löscher W, Hönack D. Effects of the novel 5-HT1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur J Pharmacol. 1993 Sep 21;242(1):99-104. PubMed PMID: 8223942.

9: Rhodes KF, Dover G, Lattimer N. The antagonist actions of WAY-100135 and its enantiomers on 5-HT1A receptor-mediated hyperpolarization of the rat isolated superior cervical ganglion. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):225-7. PubMed PMID: 8232599.

10: Chaouloff F, Aguerre S, Mormede P. GR 127935 and (+)-WAY 100135 do not affect TFMPP-induced inhibition of 5-HT synthesis in the midbrain and hippocampus of Wistar-Kyoto rats. Neuropharmacology. 1998 Sep;37(9):1159-67. PubMed PMID: 9833646.

11: Davidson C, Ho M, Price GW, Jones BJ, Stamford JA. (+)-WAY 100135, a partial agonist, at native and recombinant 5-HT1B/1D receptors. Br J Pharmacol. 1997 Jun;121(4):737-42. PubMed PMID: 9208142; PubMed Central PMCID: PMC1564750.

12: Fornal CA, Metzler CW, Gallegos RA, Veasey SC, McCreary AC, Jacobs BL. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135. J Pharmacol Exp Ther. 1996 Aug;278(2):752-62. PubMed PMID: 8768728.

13: Bell R, Mitchell PJ, Hobson H. Effects of the 5-HT1A antagonist (+)-WAY-100135 on murine social and agonistic behavior. Pharmacol Biochem Behav. 1996 May;54(1):159-67. PubMed PMID: 8728553.

14: Carli M, Luschi R, Samanin R. (S)-WAY 100135, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal scopolamine. Eur J Pharmacol. 1995 Sep 5;283(1-3):133-9. PubMed PMID: 7498302.

15: Routledge C, Gurling J, Ashworth-Preece MA, Dourish CT. Differential effects of WAY-100135 on the decrease in 5-hydroxytryptamine release induced by buspirone and NAN-190. Eur J Pharmacol. 1995 Apr 4;276(3):281-4. PubMed PMID: 7601215.

16: Löscher W, Richter A. The novel selective and silent 5-HT1A receptor antagonist (+)-WAY-100135 aggravates dystonic movements in a mutant hamster model. Eur J Pharmacol. 1994 Apr 1;255(1-3):235-8. PubMed PMID: 8026548.

17: Escandon NA, Zimmermann DC, McCall RB. Characterization of the serotonin1A receptor antagonist activity of WAY-100135 and spiperone. J Pharmacol Exp Ther. 1994 Jan;268(1):441-7. PubMed PMID: 8301586.

18: Przegaliński E, Filip M, Budziszewska B, Chojnacka-Wójcik E. Antagonism of (+)WAY 100135 to behavioral, hypothermic and corticosterone effects induced by 8-OH-DPAT. Pol J Pharmacol. 1994 Jan-Apr;46(1-2):21-7. PubMed PMID: 7981767.

19: Cliffe IA, Brightwell CI, Fletcher A, Forster EA, Mansell HL, Reilly Y, Routledge C, White AC. (S)-N-tert-butyl-3-(4-(2-methoxyphenyl)-piperazin-1-yl)-2-phenylpropanamide [(S)-WAY-100135]: a selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. J Med Chem. 1993 May 14;36(10):1509-10. PubMed PMID: 8496920.